COMPASS Pathways (NASDAQ:CMPS) Rating Reiterated by Cantor Fitzgerald

COMPASS Pathways (NASDAQ:CMPS - Get Free Report)'s stock had its "overweight" rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports.

CMPS has been the topic of a number of other reports. HC Wainwright reaffirmed a "buy" rating and set a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Morgan Stanley initiated coverage on COMPASS Pathways in a report on Monday, April 1st. They issued an "overweight" rating and a $30.00 target price for the company. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $47.40.

COMPASS Pathways Trading Down 1.3 %

Shares of NASDAQ:CMPS traded down $0.11 during midday trading on Thursday, reaching $8.42. The company's stock had a trading volume of 291,553 shares, compared to its average volume of 694,219. The firm has a market capitalization of $521.53 million, a price-to-earnings ratio of -3.60 and a beta of 2.48. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The firm has a 50 day moving average price of $10.03 and a two-hundred day moving average price of $8.34. COMPASS Pathways has a fifty-two week low of $5.01 and a fifty-two week high of $12.75.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.16). As a group, analysts forecast that COMPASS Pathways will post -2.4 earnings per share for the current year.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, Director George Jay Goldsmith sold 25,750 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $8.35, for a total transaction of $215,012.50. Following the completion of the transaction, the director now directly owns 4,172,404 shares of the company's stock, valued at $34,839,573.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other COMPASS Pathways news, Director Ekaterina Malievskaia sold 11,862 shares of the stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $10.06, for a total transaction of $119,331.72. Following the sale, the director now owns 4,110,338 shares in the company, valued at $41,350,000.28. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director George Jay Goldsmith sold 25,750 shares of the stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $8.35, for a total value of $215,012.50. Following the sale, the director now owns 4,172,404 shares in the company, valued at approximately $34,839,573.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 186,556 shares of company stock valued at $1,715,361. Company insiders own 23.99% of the company's stock.

Institutional Investors Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter worth $33,000. UBS Group AG raised its position in shares of COMPASS Pathways by 249.1% in the fourth quarter. UBS Group AG now owns 4,291 shares of the company's stock worth $34,000 after buying an additional 3,062 shares in the last quarter. Quantbot Technologies LP raised its position in shares of COMPASS Pathways by 156.8% in the first quarter. Quantbot Technologies LP now owns 3,338 shares of the company's stock worth $43,000 after buying an additional 2,038 shares in the last quarter. Advisor Group Holdings Inc. raised its position in shares of COMPASS Pathways by 129.7% in the fourth quarter. Advisor Group Holdings Inc. now owns 5,406 shares of the company's stock worth $43,000 after buying an additional 3,052 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in COMPASS Pathways by 229.6% during the third quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company's stock valued at $58,000 after purchasing an additional 5,466 shares in the last quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.